A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing on how the agency’s bureaucracy affects innovation.
- Home |
- ‘Like talking to a brick wall’: Senate hearing takes aim at FDA’s rare disease review process
‘Like talking to a brick wall’: Senate hearing takes aim at FDA’s rare disease review process
- February 26, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
